Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosuzumab reduce fracture risk after menopause.
1. Use of bisphosphonates, denosumab, abaloparatide, teriparatide, and romosuzumab is associated with reduced clinical fractures in postmenopausal osteoporotic patients. 2. Abaloparatide and teriparatide may increase the risk of adverse events associated with withdrawal. Directory rating level: 1 (Excellent) Study rundown: Osteoporosis results in weaker bones and an increased susceptibility to fractures. By standard definition, it … Read more